Abrocitinib clinical trials
Abrocitinib is named as an intervention in 11 current clinical trials in our USA, China, Germany, Spain, Poland, Mexico, Japan, France, Canada, Australia, South Korea and Israel registers. 9 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Pfizer (6). The most-studied condition is Atopic Dermatitis.
Where Abrocitinib is approved
All regulators →Of the three regulators tracked here, the first to approve Abrocitinib was the EU, on 9 Dec 2021. It is approved in 3 of the 3 regulators tracked here.
- 1 EU safety letter (DHPC), latest: referral - article 20 procedure for Cibinqo / Jyseleca / Olumiant / Rinvoq / Xeljanz, 21 Feb 2023
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Abrocitinib patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Abrocitinib, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 3 listed patents; the last listed expires 14 Jan 2036 (US 9035074).
- Latest patent on the drug substance itself: 14 Jan 2036 (US 9035074).
- Exclusivity NCE: New chemical entity, until 14 Jan 2027.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Abrocitinib
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Abrocitinib works
All drug targets →- Tyrosine-protein kinase JAK1 inhibitor InhibitorTarget: JAK1 Janus kinase 1✓ In ChEMBL and the Guide to Pharmacology
- FatiguePhase 2
- Alopecia areataPhase 2
- Granuloma annularePhase 2
- Hand eczemaPhase 2
- Lupus erythematosusPhase 2
- Prurigo nodularisPhase 2
- PsoriasisPhase 2
- Skin sarcoidosisPhase 2
- Systemic lupus erythematosusPhase 2
- Type 1 diabetes mellitusPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3655081, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9991, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Abrocitinib
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Abrocitinib. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis NICE TA814 | Optimised | 3 Aug 2022 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Abrocitinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 3 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: CibinqoEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Abrocitinib
- ChEMBL
- CHEMBL3655081
- DrugBank
- DB14973
- PubChem CID
- 78323835
- CAS number
- 1622902-68-4
- Wikidata
- Q76656815
- Wikipedia
- Abrocitinib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Abrocitinib
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Abrocitinib across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
3 single-substance products containing Abrocitinib on the HPRA medicines list.
- Cibinqo 100 mg film-coated tabletsPfizer Europe MA EEIG · EU/1/21/1593/006-010
- Cibinqo 200 mg film-coated tabletsPfizer Europe MA EEIG · EU/1/21/1593/011-015
- Cibinqo 50 mg film-coated tabletsPfizer Europe MA EEIG · EU/1/21/1593/001-005
Supply shortages
No entry for Abrocitinib in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Abrocitinib
10 conditionsSponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Abrocitinib trials
How many clinical trials are testing Abrocitinib?
11 current trials in our USA, China, Germany, Spain, Poland, Mexico, Japan, France, Canada, Australia, South Korea and Israel registers name Abrocitinib (also registered as PF-04965842) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Abrocitinib trials recruiting patients?
Yes. 9 of the 11 trials are recruiting: 4 with sites in USA, 3 with sites in China, 3 with sites in Germany, 2 with sites in Spain, 2 with sites in Poland, 2 with sites in Mexico, 2 with sites in Japan, 1 with sites in France and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Abrocitinib clinical trials?
Pfizer (6), Second Affiliated Hospital, Zhejiang University, School of Medicine (1), Universitätsklinikum Hamburg-Eppendorf (1) and Prof. Dr. Stephan Weidinger (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Abrocitinib licensed in Ireland?
Yes. The HPRA medicines list includes 3 single-substance products containing Abrocitinib, for example Cibinqo 100 mg film-coated tablets (Pfizer Europe MA EEIG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Abrocitinib shortage?
Not in the lists we track: Abrocitinib has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Abrocitinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Abrocitinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Abrocitinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.